Study of XL999 in Patients With Metastatic Colorectal Cancer

Stopped early · Phase 2

Conditions studied: Colorectal Cancer

In brief

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Key facts

Study ID

NCT00277303

Run by

Symphony Evolution, Inc.

People needed

17

Starts

2005-12-01

Expected to finish

2007-02-01

Last updated by the study team

2010-02-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females with histologically confirmed metastatic colorectal cancer
• Measurable disease according to Response Criteria for Solid Tumors (RECIST)
• At least 1 prior therapeutic regimen (chemotherapy or biologic)
• ECOG performance status of 0 or 1
• Life expectancy ≥3 months
• Adequate organ and marrow function
• No other malignancies within 5 years
• Signed informed consent

You may not qualify if…

• Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
• Treatment with systemic anticancer therapy within 30 days of XL999 treatment
• Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered >30 days prior to study enrollment
• History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
• Uncontrolled and/or intercurrent illness
• Pregnant or breastfeeding females
• Known HIV

Where it is running

• California Cancer Care, Inc. — Greenbrae, California, United States
• Integrated Community Oncology Network; Division of Clinical Research — Jacksonville, Florida, United States
• Hematology Oncology Associated of the Treasure Coast — Port Saint Lucie, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Joliet Oncology-Hematology Associated, Ltd. — Joliet, Illinois, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Hematology Oncology Associates of Rockland, PC — New City, New York, United States
• Center for Oncology Research and Treatment, PA — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.